JP2016537394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537394A5 JP2016537394A5 JP2016533614A JP2016533614A JP2016537394A5 JP 2016537394 A5 JP2016537394 A5 JP 2016537394A5 JP 2016533614 A JP2016533614 A JP 2016533614A JP 2016533614 A JP2016533614 A JP 2016533614A JP 2016537394 A5 JP2016537394 A5 JP 2016537394A5
- Authority
- JP
- Japan
- Prior art keywords
- fluorophenyl
- pyrazolo
- sulfonyl
- isoquinolin
- octahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 claims description 26
- FKNSTSIMTSEJOD-UHFFFAOYSA-N 4-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=NC(C=O)=C1 FKNSTSIMTSEJOD-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- WRFKSVINLIQRKF-UHFFFAOYSA-N 1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC=N1 WRFKSVINLIQRKF-UHFFFAOYSA-N 0.000 claims description 8
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 8
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- -1 5-thiazole Chemical compound 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 150000003852 triazoles Chemical class 0.000 claims description 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims description 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 2
- UAKMHSRHDUBNJR-UHFFFAOYSA-N 4-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=NC(C=O)=C1 UAKMHSRHDUBNJR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- XOABHRHUHPEGKJ-KMRXNPHXSA-N [(4aR,8aS)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-pyridin-2-ylmethanone Chemical compound Fc1ccc(cc1)-n1ncc2C[C@@]3(CN(CC[C@H]3Cc12)S(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)c1ccccn1 XOABHRHUHPEGKJ-KMRXNPHXSA-N 0.000 claims description 2
- CABSVADZAWZSLR-DCFHFQCYSA-N [(4ar,8as)-1-(4-fluorophenyl)-6-(2-propyltriazol-4-yl)sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-pyridin-2-ylmethanone Chemical compound CCCN1N=CC(S(=O)(=O)N2C[C@]3(CC4=C(N(N=C4)C=4C=CC(F)=CC=4)C[C@@H]3CC2)C(=O)C=2N=CC=CC=2)=N1 CABSVADZAWZSLR-DCFHFQCYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033379 Chorioretinopathy Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 231100000867 compulsive behavior Toxicity 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000021011 postpartum psychosis Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908333P | 2013-11-25 | 2013-11-25 | |
| US61/908,333 | 2013-11-25 | ||
| US201461985035P | 2014-04-28 | 2014-04-28 | |
| US61/985,035 | 2014-04-28 | ||
| PCT/US2014/066759 WO2015077530A1 (en) | 2013-11-25 | 2014-11-21 | Octahydro fused azadecalin glucocorticoid receptor modulators |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206081A Division JP2018012734A (ja) | 2013-11-25 | 2017-10-25 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2019063279A Division JP2019094355A (ja) | 2013-11-25 | 2019-03-28 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537394A JP2016537394A (ja) | 2016-12-01 |
| JP2016537394A5 true JP2016537394A5 (enExample) | 2017-12-07 |
| JP6516743B2 JP6516743B2 (ja) | 2019-05-22 |
Family
ID=53180165
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533614A Active JP6516743B2 (ja) | 2013-11-25 | 2014-11-21 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2017206081A Pending JP2018012734A (ja) | 2013-11-25 | 2017-10-25 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2019063279A Withdrawn JP2019094355A (ja) | 2013-11-25 | 2019-03-28 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2021021630A Withdrawn JP2021073315A (ja) | 2013-11-25 | 2021-02-15 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2022189246A Withdrawn JP2023011052A (ja) | 2013-11-25 | 2022-11-28 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2024148322A Withdrawn JP2024170470A (ja) | 2013-11-25 | 2024-08-30 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2026038048A Pending JP2026094404A (ja) | 2013-11-25 | 2026-03-10 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206081A Pending JP2018012734A (ja) | 2013-11-25 | 2017-10-25 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2019063279A Withdrawn JP2019094355A (ja) | 2013-11-25 | 2019-03-28 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2021021630A Withdrawn JP2021073315A (ja) | 2013-11-25 | 2021-02-15 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2022189246A Withdrawn JP2023011052A (ja) | 2013-11-25 | 2022-11-28 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2024148322A Withdrawn JP2024170470A (ja) | 2013-11-25 | 2024-08-30 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| JP2026038048A Pending JP2026094404A (ja) | 2013-11-25 | 2026-03-10 | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US10047082B2 (enExample) |
| EP (5) | EP4717266A3 (enExample) |
| JP (7) | JP6516743B2 (enExample) |
| KR (1) | KR102352737B1 (enExample) |
| CN (2) | CN106029066B (enExample) |
| AU (1) | AU2014352915B2 (enExample) |
| BR (1) | BR112016011826B1 (enExample) |
| CA (1) | CA2931302C (enExample) |
| DK (2) | DK3848027T3 (enExample) |
| ES (4) | ES2943542T3 (enExample) |
| FI (1) | FI3848027T3 (enExample) |
| IL (1) | IL245848B (enExample) |
| MX (1) | MX368167B (enExample) |
| MY (1) | MY180141A (enExample) |
| PH (1) | PH12016500968B1 (enExample) |
| PL (3) | PL3848027T3 (enExample) |
| PT (2) | PT3848027T (enExample) |
| RU (1) | RU2674983C1 (enExample) |
| WO (1) | WO2015077530A1 (enExample) |
| ZA (1) | ZA201604026B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2943542T3 (es) | 2013-11-25 | 2023-06-14 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| JP6754533B2 (ja) | 2015-03-30 | 2020-09-16 | コーセプト セラピューティクス， インコーポレイテッド | 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用 |
| AU2017228329B2 (en) | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| CN106478464B (zh) * | 2016-08-30 | 2018-06-05 | 黄河三角洲京博化工研究院有限公司 | 一种2-氟-6-三氟甲基苯磺酰氯的制备方法 |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| CA3053806A1 (en) | 2017-03-09 | 2018-09-13 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| WO2018236749A2 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| CN117771239A (zh) * | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| IL278125B (en) * | 2018-04-23 | 2022-09-01 | Corcept Therapeutics Inc | Methods for the preparation of regioselective n-alkyl triazoles |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| NZ778399A (en) | 2019-02-22 | 2024-11-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| AU2020367769B2 (en) | 2019-10-16 | 2023-10-12 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| AU2020408057B2 (en) | 2019-12-21 | 2026-01-29 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, ACTH-Dependent Cushing's syndrome and ACTH-Independent Cushing's syndrome |
| AU2021214938B2 (en) | 2020-01-29 | 2024-02-08 | Corcept Therapeutics Incorporated | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors |
| JP2023515781A (ja) * | 2020-02-10 | 2023-04-14 | コーセプト セラピューティクス， インコーポレイテッド | 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法 |
| EP4157276A4 (en) | 2020-05-27 | 2024-06-12 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| IL298957A (en) | 2020-06-22 | 2023-02-01 | Corcept Therapeutics Inc | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| TW202246260A (zh) * | 2021-02-03 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| KR20240125035A (ko) | 2021-12-21 | 2024-08-19 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 이환 인다졸 글루코코르티코이드 수용체 길항제 |
| MX2024007590A (es) | 2021-12-21 | 2024-08-20 | Corcept Therapeutics Inc | Antagonistas piperazino indazólicos del receptor de glucocorticoides. |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| WO2024077169A1 (en) | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| AU2024223250A1 (en) * | 2023-02-17 | 2025-08-14 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
| WO2024243185A1 (en) * | 2023-05-22 | 2024-11-28 | Corcept Therapeutics Incorporated | Methods for treating adrenal gland tumors |
| CN122580311A (zh) * | 2024-01-15 | 2026-08-14 | 英矽智能科技知识产权有限公司 | 作为糖皮质激素受体调节剂的新化合物及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (enExample) | 1954-11-30 | 1957-04-11 | ||
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| DE69430373T2 (de) | 1993-08-06 | 2002-12-12 | Smithkline Beecham S.P.A., Baranzate Di Bollate | Hydroisochinolinderivate |
| JP4498602B2 (ja) | 1998-03-10 | 2010-07-07 | リサーチ・トライアングル・インスティチュート | 新規なオピエート化合物、その調製法及び使用法 |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| EP1333842B1 (en) * | 2000-11-02 | 2006-08-30 | Akzo Nobel N.V. | Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| CN1547473A (zh) * | 2001-07-23 | 2004-11-17 | �Ƹ��� | 预防由抗精神病药物引起的体重增加的方法 |
| US6679935B2 (en) * | 2001-08-14 | 2004-01-20 | Apex Advanced Technologies, Llc | Lubricant system for use in powdered metals |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
| CA2552419C (en) | 2004-01-09 | 2013-04-23 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| JP4931794B2 (ja) * | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス， インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| WO2006106052A1 (en) * | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| JP2011503081A (ja) | 2007-11-01 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用 |
| CN101990541A (zh) * | 2008-02-07 | 2011-03-23 | 百时美施贵宝公司 | 糖皮质激素受体、AP-1和/或NF-κB活性的稠合杂芳基调节剂及其用途 |
| AU2010247766B2 (en) | 2009-05-12 | 2015-05-21 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| BR112013004322A2 (pt) * | 2010-08-27 | 2016-06-21 | Corcept Therapeutics Inc | moduladores de azadecalin fundidos com piridil-aminas |
| WO2012094618A1 (en) | 2011-01-07 | 2012-07-12 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| NZ701469A (en) * | 2012-05-25 | 2017-06-30 | Corcept Therapeutics Inc | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2943542T3 (es) * | 2013-11-25 | 2023-06-14 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2014
- 2014-11-21 ES ES21158231T patent/ES2943542T3/es active Active
- 2014-11-21 ES ES19177963T patent/ES2869172T3/es active Active
- 2014-11-21 ES ES23157691T patent/ES3067617T3/es active Active
- 2014-11-21 CN CN201480074087.5A patent/CN106029066B/zh active Active
- 2014-11-21 US US14/549,885 patent/US10047082B2/en active Active
- 2014-11-21 EP EP26157935.3A patent/EP4717266A3/en active Pending
- 2014-11-21 CA CA2931302A patent/CA2931302C/en active Active
- 2014-11-21 DK DK21158231.7T patent/DK3848027T3/da active
- 2014-11-21 WO PCT/US2014/066759 patent/WO2015077530A1/en not_active Ceased
- 2014-11-21 AU AU2014352915A patent/AU2014352915B2/en active Active
- 2014-11-21 CN CN201910143177.XA patent/CN109761976B/zh active Active
- 2014-11-21 JP JP2016533614A patent/JP6516743B2/ja active Active
- 2014-11-21 PL PL21158231.7T patent/PL3848027T3/pl unknown
- 2014-11-21 FI FIEP21158231.7T patent/FI3848027T3/fi active
- 2014-11-21 PT PT211582317T patent/PT3848027T/pt unknown
- 2014-11-21 PL PL19177963T patent/PL3560493T3/pl unknown
- 2014-11-21 EP EP14863514.7A patent/EP3074011B1/en active Active
- 2014-11-21 EP EP19177963.6A patent/EP3560493B1/en active Active
- 2014-11-21 MY MYPI2016000978A patent/MY180141A/en unknown
- 2014-11-21 EP EP21158231.7A patent/EP3848027B1/en active Active
- 2014-11-21 DK DK14863514.7T patent/DK3074011T3/da active
- 2014-11-21 ES ES14863514T patent/ES2743620T3/es active Active
- 2014-11-21 RU RU2016123449A patent/RU2674983C1/ru active
- 2014-11-21 EP EP23157691.9A patent/EP4219494B1/en active Active
- 2014-11-21 BR BR112016011826-0A patent/BR112016011826B1/pt active IP Right Grant
- 2014-11-21 PT PT14863514T patent/PT3074011T/pt unknown
- 2014-11-21 PL PL14863514T patent/PL3074011T3/pl unknown
- 2014-11-21 MX MX2016006725A patent/MX368167B/es active IP Right Grant
- 2014-11-21 KR KR1020167017023A patent/KR102352737B1/ko active Active
-
2016
- 2016-05-24 PH PH12016500968A patent/PH12016500968B1/en unknown
- 2016-05-25 IL IL245848A patent/IL245848B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04026A patent/ZA201604026B/en unknown
-
2017
- 2017-10-25 JP JP2017206081A patent/JP2018012734A/ja active Pending
-
2018
- 2018-07-16 US US16/036,001 patent/US20190135805A1/en not_active Abandoned
- 2018-10-16 US US16/161,642 patent/US10323034B2/en active Active
-
2019
- 2019-03-28 JP JP2019063279A patent/JP2019094355A/ja not_active Withdrawn
- 2019-04-12 US US16/382,474 patent/US10787449B2/en active Active
-
2020
- 2020-08-04 US US16/984,914 patent/US11370789B2/en active Active
-
2021
- 2021-01-12 US US17/146,608 patent/US11560379B2/en active Active
- 2021-02-15 JP JP2021021630A patent/JP2021073315A/ja not_active Withdrawn
-
2022
- 2022-11-28 JP JP2022189246A patent/JP2023011052A/ja not_active Withdrawn
- 2022-12-09 US US18/078,389 patent/US12139486B2/en active Active
-
2024
- 2024-08-30 JP JP2024148322A patent/JP2024170470A/ja not_active Withdrawn
- 2024-10-04 US US18/906,346 patent/US20250034140A1/en active Pending
-
2026
- 2026-03-10 JP JP2026038048A patent/JP2026094404A/ja active Pending